7/10/2019
1
#FSHP2019
To PADIS and Beyond: Updates and Integration To PADIS and Beyond: Updates and Integration Michael Semanco, PharmD, BCPS, BCCCPClinical Pharmacy Specialist – Critical CareLakeland Regional HealthAugust 3, 2019
#FSHP2019DisclosureDisclosureI do not have (nor does any immediate family member have):• a vested interest in or affiliation with any corporate
organization offering financial support or grant monies for this presentation
• any affiliation with an organization whose philosophy could potentially bias this presentation
#FSHP2019ObjectivesObjectivesHighlight changes from PAD to PADIS with a focus on new recommendations
Explore the potential uses of nefopam and ketamine for the treatment of pain and agitation in the intensive care unit
Develop strategies to implement, integrate, and evaluate the implementation of the new guidelines
#FSHP2019TimelineTimeline
1990 2000 2010 2020
19956 recommendations
13 references
201354 statements472 references
201874 statements538 references
200228 recommendations
235 referencesGuidelines
#FSHP20192018 Guidelines2018 GuidelinesPainAgitation / SedationDeliriumImmobility (Rehabilitation / Mobilization)Sleep Disruption
PADIS
Devlin et al. Crit Care Med 2018;46:e825-e873.
#FSHP2019MethodsMethodsWorking group (multidisciplinary):• 32 experts from 5 countries• 4 methodologists• 4 critical illness survivors• 2 medical librarians• 2 SCCM staff
Balas et al. Crit Care Med 2018;46:1464-1470.Devlin et al. Crit Care Med 2018;46:1457-1463.
StatementsLiterature GRADEQuestions
1 2
3 4
5 6
7/10/2019
2
#FSHP2019MethodsMethods• 5 topic-based groups developed: 37 recommendations (3 strong, 34 conditional) 2 good practice statements 32 ungraded statements 3 questions with no recommendation
• Need to be easily interpreted, understood, and implemented
Balas et al. Crit Care Med 2018;46:1464-1470.Devlin et al. Crit Care Med 2018;46:1457-1463.
#FSHP2019
ImmobilitySleep Disruption
PADIS
PainAgitationDelirium
PAD
SI+ =
Barr et al. Crit Care Med 2013;41:263-306.Devlin et al. Crit Care Med 2018;46:e825-e873.
#FSHP20192018 Guidelines2018 GuidelinesPainAgitation / SedationDeliriumImmobility (Rehabilitation / Mobilization)Sleep Disruption
PADIS
#FSHP2019Protocol-Based Pain Assessment and ManagementProtocol-Based Pain Assessment and Management
Devlin et al. Crit Care Med 2018;46:e825-e873.
#FSHP2019Pain AssessmentPain AssessmentTopic Strength Recommendation
Self-Report Scales Ungraded Reference standard if reliable communication
BehavioralAssessment Tools Ungraded
Unable to self-report and observable behaviors, Behavioral Pain Scale (BPS) and Critical-Care Pain Observation Tool (CPOT)
Proxy Reporters Ungraded When unable to self-report and when appropriate, family may be involved
Physiologic Measures Ungraded Vital signs are cues to initiate further assessment
Devlin et al. Crit Care Med 2018;46:e825-e873.
#FSHP2019Pain TreatmentPain TreatmentPharmacologic Adjuvant Strength Recommendation
Acetaminophen Suggest using Decrease pain intensity and opioid consumption (route?)
Nefopam Suggest using Opioid adjunct or replacement to reduce use and alleviate safety concerns
Ketamine Suggest using Low-dose as an adjunct to opioids in post-surgical
Neuropathic Pain Recommend using With opioids for neuropathic pain (e.g., gabapentin, carbamazepine, and pregabalin)
Lidocaine Suggest not routinely using As an adjunct to opioids
NSAIDs Suggest not routinely using COX-1-selective as an adjunct
Devlin et al. Crit Care Med 2018;46:e825-e873.
7 8
9 10
11 12
7/10/2019
3
#FSHP2019NefopamNefopam
Evans et al. Br J Anaesth 2008;101:610-617.https://us.lgcstandards.com/US/en/Nefopam-Hydrochloride/p/MM1189.00
https://www.digital-pharmacie.ma/on-ma-donne-de-lacupan-injectable-a-boire
#FSHP2019Mechanism of ActionMechanism of Action
Kim et al. Korean J Pain 2014;27:103-111.Girard et al. Clin Exp Pharmacol Physiol 2016;43:3-12.
#FSHP2019BenzoxazocineBenzoxazocine
Evans et al. Br J Anaesth 2008;101:610-617.https://www.sciencedirect.com/topics/medicine-and-dentistry/nefopam
#FSHP2019PK / PDPK / PD• Administration: IV, IM, oral• Bioavailability: 40%• Peak (IV): 15-20 minutes• Half-life: 3-5 hours• Protein binding: 75%• Metabolism: Hepatic Active & non-active metabolites
• Elimination Renal 87% Feces 8%
Evans et al. Br J Anaesth 2008;101:610-617.https://www.cyprotex.com/insilico/physiological_modelling/chempk
#FSHP2019DosingDosing• IV / IM: 20mg q 6hrs• Oral: 30-90mg tid
• Opioid comparison: 20mg nefopam = 6 mg morphine Morphine sparing effect = 30-50%
Evans et al. Br J Anaesth 2008;101:610-617.Chanques et al. Br J Anaesth 2011;106:336-343.
Acuten [package insert]. ACI Limited. Available at http://www.aci-bd.com/Brand/Acuten.
#FSHP2019Adverse ReactionsAdverse Reactions• Tachycardia• Hypertension• Urine retention• Sweating• Dry mouth• Nausea
• Vomiting• Hot flushes• Heat sensation• Confusion• Convulsions • Drowsiness
Chanques et al. Br J Anaesth 2011;106:336-343.Evans et al. Br J Anaesth 2008;101:610-617.
Girard et al. Clin Exp Pharmacol Physiol 2016;43:3-12.
13 14
15 16
17 18
7/10/2019
4
#FSHP2019ClinicalTrials.govClinicalTrials.govAs of May 2019• Nefopam -> 25 studies• Nefopam + Intensive Care Unit -> 0 studies• Nefopam + Critically ill -> 0 studies
• Nefopam + United States -> 0 studies
https://clinicaltrials.gov
#FSHP2019Future of NefopamFuture of Nefopam
#FSHP2019NonpharmacologicNonpharmacologicTopic Strength Recommendation
Cybertherapy / Hypnosis
Suggest not offering For pain management in ICU
Massage Suggest offering For pain management in ICU
Music Suggest offering For both nonprocedural and procedural pain
Cold Therapy Suggest offering For procedural pain management
Relaxation Techniques Suggest offering For procedural pain management
Devlin et al. Crit Care Med 2018;46:e825-e873.
#FSHP20192018 Guidelines2018 GuidelinesPainAgitation / SedationDeliriumImmobility (Rehabilitation / Mobilization)Sleep Disruption
PADIS
#FSHP2019Agitation / SedationAgitation / SedationTopic Strength Recommendation
Light Sedation Suggest using In critically ill, mechanically ventilated adults
DSI protocols / NP-Targeted sedation Ungraded Both can achieve and maintain light levels
of sedationCardiac Surgery (Prop vs BDZ) Suggest using Propofol over benzodiazepine
Non-Cardiac Surgery (Prop vs Dex vs BDZ) Suggest using Either propofol or dexmedetomidine over
benzodiazepines
Devlin et al. Crit Care Med 2018;46:e825-e873.
DSI = Daily Sedative InterruptionNP = Nursing-protocolized
#FSHP2019
https://www.medicalnewstoday.com/articles/322909.php
19 20
21 22
23 24
7/10/2019
5
#FSHP2019IndicationsIndications• Dissociative anesthesia• Acute pain management• Chronic pain management• Local anesthetic• Procedural sedation• Rapid sequence intubation• Alcohol withdrawal• ICU sedation• Analgosedation• Refractory status epilepticus• Bronchodilatation• Major depression
Patanwala et al. J Intensive Care Med 2017;32:387-395.Erstad et al. J Crit Care 2016;35:145-149.
#FSHP2019Mechanism of ActionMechanism of ActionAntagonism / Inhibition Effects
NMDA receptorsDissociative anesthesia, amnesiaInhibited sensory perceptionAnalgesia
HCN channels Hypnosis
Calcium channels (L-type voltage-dependent) Negative inotropy
Voltage-gated sodium channels Decreased parasympathetic activityLocal anesthetic effect
BK channels Neuropathic pain
Agonism / Activation EffectsOpioid receptors (µ, Κ) Central antinociception
AMPA receptors Rapid antidepressant effects
GABAA receptors Anesthetic properties
Li et al. Front Hum Neurosci 2016;10:612-626.HCN = hyperpolarization-activated cyclic nucleotideBK = large-conductance potassium channelsAMPA = alpha-amino-3-hydroxyl-5-methyl-4-isoxazolepropionic acid
#FSHP2019
Zanos et al. Molecular Psychiatry 2018;23:801-811.
#FSHP2019NeuropharmacologyNeuropharmacology
Erstad et al. J Crit Care 2016;35:145-149.
HCN1 = hyperpolarization-activated cyclic nucleotide channels
Ach = acetylcholinenACh = nicotinic acetylcholine receptorsAMPA = alpha-amino-3-hydroxyl-5-
methylisoxazole-4-propionic acidmGluR = metabotropic glutamate receptorsERK1/2 = extracellular signal-regulated kinasesNOX = NADPH oxidaseBDNF = brain-derived neurotrophic factormTOR = mammalian target of rapamycinRgs4 = regulator of G protein signaling 4L-type Ca2 = L-type calcium channelsGFAP = glial fibrillary acidic protein
Abbreviations
#FSHP2019PK / PDPK / PD• Administration: IV, IM, oral, intranasal, rectal• Onset (IV): within 30 seconds• Duration: Anesthetic: 5-10 minutes Recovery: 1-2 hours
• Half-life elimination: 10-15min vs 2.5hrs• VD: 2.4L/kg• Protein binding: 27%• Metabolism: Hepatic via P450 Active metabolite: norketamine (33% potency)
Erstad et al. J Crit Care 2016;35:145-149.Ketamine. Lexi-Drugs. Lexi-comp. Wolters Kluwer Health, Inc.
https://www.cyprotex.com/insilico/physiological_modelling/chempk
#FSHP2019DosingDosingIndication and Reference Specific• Anesthesia: Induction -> 0.5-4.5 mg/kg IVP Maintenance -> 0.1-6 mg/min (depending on adjuvants)
• Procedural sedation/analgesia: 0.5-2 mg/kg IVP• Intensive Care Unit: Opioid adjunct -> 0.5 mg/kg IV then 1-2 mcg/kg/min (0.06-0.12 mg/kg/hr) Sedation -> 0.5-2 mg/kg IV then 0.5-5 mg/kg/hr (8.3-83.3 mcg/kg/min)
Devlin et al. Crit Care Med 2018;46:e825-e873.Ketamine. Lexi-Drugs. Lexi-comp. Wolters Kluwer Health, Inc.
Ketamine. Micromedex Solutions. Truven Health Analytics, Inc.
25 26
27 28
29 30
7/10/2019
6
#FSHP2019Adverse ReactionsAdverse Reactions• Emergence• Tachycardia • Dysrhythmias• Hypertension• Hypotension• Hypersalivation• Heart failure• Nystagmus
• Diplopia• Anaphylaxis• Nausea• Vomiting• Increased IOP• Respiratory depression• Laryngeal spasm• Drug abuse
Erstad et al. J Crit Care 2016;35:145-149.Ketamine. Lexi-Drugs. Lexi-comp. Wolters Kluwer Health, Inc.
Ketamine. Micromedex Solutions. Truven Health Analytics, Inc.
#FSHP2019Clinical EffectsClinical EffectsAdvantages• Sympathomimetic (HR, BP)• Lacks respiratory depression• Pharyngeal and laryngeal reflexes• Lowers airway resistance• Increases lung compliance• No GIB (vs. NSAIDS)• No AKI (vs. NSAIDS)• No constipation (vs. opioids)• No ICP interactions• Cost
Disadvantages• Psychotomimetic (emergence reactions)• Aggravate pulmonary hypertension• CNS excitation• Psychiatric history• Drug withdrawal• Myocardial depression• Hydrocephalus• Hypersalivation• Legality (administration)
Erstad, et al. J Crit Care 2016;35:145-149, Miller et al. Minerva Anestesiol 2011;77:812-820.
#FSHP2019AnalgosedationAnalgosedationAnalgesia-based or Analgesia-first sedation
“Emphasis is placed on relieving pain and discomfort prior to instituting sedative-hypnotic agents that do not have analgesic properties”
Devabhakthuni et al. Ann Pharmacother 2012;46:530-540.Patanwala et al. J Intensive Care Med 2017;32:387-395.
#FSHP2019
Impact of Ketamine Use on Adjunctive Analgesic and Sedative Medications in Critically Ill Trauma Patients
Objective Examine the impact of ketamine infusions on sedative and analgesics in mechanically ventilated critically ill trauma patients
Methods• Single center, retrospective study (2014-2015)• Included ICU patients who received ketamine continuous infusions• Excluded indications other than ICU sedation and agitation
Results(n=36)
• Avg. ketamine (mg/kg/hr): < 24 hrs (0.64), 24-48 hrs (0.81), and 48-72 hrs (0.94)• 72 hrs pre-ketamine vs 72 hrs post-ketamine:
No ∆ RASS goal, midazolam equivalents, IV haloperidol or quetiapine Less morphine equivalents (p=0.026) and propofol (p=0.002) More dexmedetomidine (p=0.002) and ziprasidone (p=0.018)
Conclusions Routine use of ketamine should not be recommended until large prospective studies assess efficacy and safety and determine the ideal dosing strategy
Pruskowski et al. Pharmacotherapy 2017;37:1537-1544.
#FSHP2019
Ketamine Infusion for Adjunct Sedation in Mechanically Ventilated Adults
Objective Describe experience using ketamine infusions as adjunct sedation targeting light levels of sedation in mechanically ventilated critically ill patients
Methods
• Single center, retrospective study (2012-2016)• Receiving continuous sedation or analgesia with goal SAS 3-4• Ketamine infusion for at least 6 hrs• Excluded deep sedation and nonsedation indications
Results(n=91)
• Ketamine – start 0.1 mg/kg/hr with median 0.41 mg/kg/hr for 2.8 days• Reduced or discontinued sedatives without initiation of another at 24 hrs (63%)• Increased SAS scores at goal (pre-24hr vs post-24hr) (p=0.001)• No difference in rates of ADRs, < 8% with ketamine
Conclusions Continuous infusion ketamine is well tolerated with an acceptable safety profile when used for adjunct sedation in critically ill adults
Groetzinger et al. Pharmacotherapy 2018;38:181-188.
#FSHP2019
Continuous Infusion Ketamine for Adjunctive Analgosedation in Mechanically Ventilated, Critically Ill Patients
Objective Adjunctive ketamine will decrease concomitant analgesic/sedative infusions and increase or maintain time within goal sedation range
Methods• Two-center, retrospective study (2016-2017)• One analgesic or sedative infusion with ketamine infusion for at least 24hrs• Excluded status epilepticus and NMB administration
Results(n=104)
• Ketamine – median 5 mcg/kg/min for 90.5 hrs (max 7 mcg/kg/min @ 72 hrs)• 20% reduction of concomitant analgesics and sedatives (p=0.001)• Improved time in goal RASS (7.1% pre- vs. 25% post-ketamine) (p=0.005)• No difference median RASS, # RASS assessments, or CAM-ICU• If vasopressors (n=12), 70.5% had decrease or discontinue with ketamine• No difference responders vs non-responders
Conclusions Ketamine infusions promote concomitant analgesic/sedative dose-sparing effects while increasing time within goal RASS in mechanically ventilated patients
Garber at al. Pharmacotherapy 2019;39:288-296.
31 32
33 34
35 36
7/10/2019
7
#FSHP2019ClinicalTrials.govClinicalTrials.govAs of May 2019• Ketamine -> 624 studies• Ketamine + Continuous infusion -> 46 studies• Ketamine + Intensive Care Unit -> 19 studies• Ketamine + Critically ill -> 7 studies• Ketamine + Analgosedation -> 3 studies
https://clinicaltrials.gov
#FSHP2019Future of Ketamine in ICUFuture of Ketamine in ICU• Procedures• Adjunct to opioids• Continuous sedation: Indications? Dosing regimens? Other effects?
• Future studies?
https://www.123rf.com/photo_110475100...
#FSHP20192018 Guidelines2018 GuidelinesPainAgitation / SedationDeliriumImmobility (Rehabilitation / Mobilization)Sleep Disruption
PADIS
#FSHP2019DeliriumDeliriumTopic Strength Recommendation
Risk Factors Ungraded Modifiable and non-modifiable
Prediction Ungraded Validated at ICU admission and in first 24 hours of ICU
Assessment Good Practice Statement Regular assessment with a validated tool
Outcomes Ungraded Screenings and delirium associated with a variety of outcomes
Devlin et al. Crit Care Med 2018;46:e825-e873.
#FSHP2019PharmacologyPharmacologyTopic Strength Recommendation
Prevention in all ICU patients Suggest not using
Haloperidol, atypical antipsychotics, dexmedetomidine, HMG-CoA reductase
inhibitors, or ketamineSubsyndromalTreatment Suggest not using Haloperidol or atypical antipsychotics
Treatment Suggest not routinely using
Haloperidol, atypical antipsychotics, or HMG-CoA reductase inhibitors
Dexmedetomidine Suggest usingDexmedetomidine if mechanically
ventilated where agitation is precluding weaning/extubation
Devlin et al. Crit Care Med 2018;46:e825-e873.
#FSHP2019NonpharmacologicNonpharmacologicTopic Strength Recommendation
Bright Light Therapy Suggest not using To reduce delirium
MulticomponentStrategy Suggest using
Focused on reducing modifiable risk factors, improving cognition, and optimizing sleep,
mobility, hearing, and vision
Devlin et al. Crit Care Med 2018;46:e825-e873.
37 38
39 40
41 42
7/10/2019
8
#FSHP20192018 Guidelines2018 GuidelinesPainAgitation / SedationDeliriumImmobility (Rehabilitation / Mobilization)Sleep Disruption
PADIS
#FSHP2019Immobility (Rehabilitation / Mobilization)Immobility (Rehabilitation / Mobilization)• ICU-acquired muscle weakness (ICUAW): 25-50% of critically ill patients Associated with long-term survival, physical functioning, and QOL
• 2013 – beneficial as part of delirium management • Current / Future: Growing literature Interplay with PAD
Devlin et al. Crit Care Med 2018;46:e825-e873.
#FSHP2019ImmobilityImmobilityTopic Strength Recommendation
Efficacy & Benefit SuggestPerforming
Either in-bed or out-of-bed improves patient, family, or health system outcomes
Safety and Risk Ungraded Serious safety events or harms do not commonly occur
Initiation Ungraded Stability of cardiovascular, respiratory, and neurologic status
Stopping Ungraded Development of new cardiovascular, respiratory, or neurologic instability
Devlin et al. Crit Care Med 2018;46:e825-e873.
#FSHP2019Safety CriteriaSafety CriteriaCardiovascular• HR: 60-130 bpm• SBP: 90-180 mmHg• MAP: 60-100 mmHgRespiratory• RR: 5-40 bpm• SpO2 ≥ 88%• FiO2 < 0.6 and PEEP <10• Secure airwayNeurologic – multipleOther – sheath, CRRT, pressors
Devlin et al. Crit Care Med 2018;46:e825-e873.
#FSHP20192018 Guidelines2018 GuidelinesPainAgitation / SedationDeliriumImmobility (Rehabilitation / Mobilization)Sleep Disruption
PADIS
#FSHP2019Sleep DisruptionSleep DisruptionICU sleep disruption• ↑ light (N1 + N2)• ↓ slow-wave (N3)• ↓ REM
Delirium sleep disruption• ? light (N1 + N2)• ? deep (N3)• ↓ REM
Devlin et al. Crit Care Med 2018;46:e825-e873.https://www.webmd.com/sleep-disorders/ss/slideshow-sleep-body-effects
43 44
45 46
47 48
7/10/2019
9
#FSHP2019CharacterizationCharacterizationHealthy ICU Delirium Mechanical
Ventilation (MV)*
Total sleep time (TST) Normal ↔ ?
Sleep efficiency Normal ↔ ↑ / ↔Circadian rhythm Abnormal Abnormal Abnormal
Sleep fragmentation ↑ ↔ ↔Daytime sleeping ↑ ↑ ↑Subjective quality ↓ ? ?
Devlin et al. Crit Care Med 2018;46:e825-e873.
MV* = effects variable and not fully investigated
#FSHP2019PharmacologicPharmacologicTopic Strength Recommendation
Melatonin No recommendation
Limited data, concerns with quality and consistency of product
Dexmedetomidine No recommendation
If hemodynamically stable, reasonable option (potential to improve sleep
architecture)
Propofol Suggest not using Solely for sleep, may use if procedural or continuous sedation required
Sleep-Promoting Protocol Suggest using Incorporate multiple interventions
Devlin et al. Crit Care Med 2018;46:e825-e873.
#FSHP2019NonpharmacologicNonpharmacologicTopic Strength Recommendation
Ventilator Mode Suggest using Assist-control (vs. pressure support) at night
Adaptive Ventilation Norecommendation Compared to pressure support
NIV-dedicated Ventilator Suggest using NIV-dedicated or standard ICU ventilator
requiring NIV to improve sleepAromatherapy / Acupressure / Music Suggest not using Compared to not using them
Noise and Light Reduction Suggest using Use at night to improve sleep
Devlin et al. Crit Care Med 2018;46:e825-e873.
NIV = Noninvasive ventilation
#FSHP2019Implement, Integrate, and EvaluateImplement, Integrate, and Evaluate• Clinician perspective: Breadth of topics Conditional nature of recommendations Most of the patients, most of the time
• Guidelines -> “what” but not “how”• How are guidelines successful?
Balas et al. Crit Care Med 2018;46:1464-1470.
#FSHP2019TimelineTimeline
1990 2000 2010 2020
1995 2013 20182002Guidelines
Bundles
2011ABCDE
2008ABC Trial
#FSHP2019ABCDEABCDE
Morandi et al. Curr Opin Crit Care 2011;17:43-49.
49 50
51 52
53 54
7/10/2019
10
#FSHP2019TimelineTimeline
1990 2000 2010 2020
1995 2013 20182002Guidelines
Bundles
2011ABCDE
2016ABCDEF
2008ABC Trial
#FSHP2019SCCM ICU LiberationSCCM ICU Liberation• Improve patient outcomes:
After an ICU stay Reduce the risk of long-term consequences (PICS)
• Empower multi-professional team• Evidence based strategy to implement guidelines• Greatest benefit when interventions combined:
Offer numerous tools and resources Components are clearly defined but flexible to implement
https://www.sccm.org/ICULiberation/AboutMarra et al. Crit Care Clin 2017;33:225-243.
#FSHP2019ABCDEF BundleABCDEF BundleAssess, Prevent, and Manage PainBoth SAT and SBTChoice of Analgesia and SedationDelirium: Assess, Prevent, and ManageEarly Mobility and ExerciseFamily Engagement and Empowerment
https://www.sccm.org/ICULiberation/ABCDEF-Bundles
ABCDEF
#FSHP2019
Pronovost et al. BMJ 2008;337:a1714.
OverviewOverview
#FSHP2019Implementation ProcessImplementation Process• Evaluate clinically / address gaps in guidelines• Begin discussions at hospital and ICU levels Gather information Involve stakeholders
• Engagement
Balas et al. Crit Care Med 2018;46:1464-1470.
#FSHP2019Key StakeholdersKey StakeholdersPhysicians Pharmacists Respiratory
Therapists
Physical Therapists Nurses Occupational
Therapists
Speech Therapists Consultants Pastoral Care
Information Technology
Patients / Family
Balas et al. Crit Care Med 2018;46:1464-1470.
55 56
57 58
59 60
7/10/2019
11
#FSHP2019StrategyStrategyPlanning• Identify early adopters, opinion leaders, and
champions• Assess current practice• Assess readiness and identify barriers• Provide metrics for tracking• Electronic medical record• Develop incentives / disincentives• Institutional buy-in (executive leadership)• Visit other sites• Develop academic partnerships• Consider participating in a collaborative
Planning
Implementation
Evaluation
Balas et al. Crit Care Med 2018;46:1464-1470.
#FSHP2019Assess Current PracticeAssess Current Practice• Walking rounds• Case reviews• Staff interviews• Perform gap analysis• Previous MUEs or DUEs• Review existing policies & procedures• Evaluate documentation• Identify committee involvement• Explore ICU culture
Balas et al. Crit Care Med 2018;46:1464-1470.https://www.123rf.com/photo_8443366_man-with-magnifying-glass.html
#FSHP2019BarriersBarriers• Strength of evidence• Implementation complexity• Administrative support• Resource availability• Clinician time• Knowledge, beliefs, skills• Education support• Financial barriers / cost• Team communication and
cooperation
• ICU culture• Priority• Guideline adaptability• Organizational incentives• Self-efficacy• Local, district, regional
comparators• International comparators• Learning framework
Balas et al. Crit Care Med 2018;46:1464-1470.
#FSHP2019StrategyStrategyImplementation• Develop formal plan• Ensure orders and documentation• Model and stimulate change• Mandate change• Provide ongoing education and outreach• Use reminders• Promote adaptability• Trial changes (PDSA)
Planning
Implementation
Evaluation
Balas et al. Crit Care Med 2018;46:1464-1470.
#FSHP2019Plan-Do-Study-Act (PDSA)Plan-Do-Study-Act (PDSA)
https://innovations.ahrq.gov/qualitytools/plan-do-study-act-pdsa-cycle
Step 1
• Plan test or observation
• Plan data collection
Step 2
• Do• Test on a
small scale
Step 3
• Study• Analyze
data and results
Step 4
• Act• Refine
change
#FSHP2019StrategyStrategyEvaluation• Audit and provide feedback (process &
outcomes)• Identify additional barriers• Tailor strategies• Use data experts• Conduct cyclical small test of change• Broaden comparators
Planning
Implementation
Evaluation
Balas et al. Crit Care Med 2018;46:1464-1470.
61 62
63 64
65 66
7/10/2019
12
#FSHP2019SustainabilitySustainability• Multiple initiatives• Goal setting• Champions• Benchmark data• Rounding checklists• Competition
Balas et al. Crit Care Med 2018;46:1464-1470.http://livingflow.ca/spinning-plate-syndrome-anxious-stressed-depressed-how-to-relieve-the-spinning/
#FSHP2019ApplicabilityApplicability
Barnes-Daly et al. Crit Care Med 2017;45:171-178.
#FSHP2019Improving Hospital Survival and Reducing Brain Dysfunction at Seven
California Community Hospitals: Implementing PAD Guidelines Via the ABCDEF Bundle in 6064 Patients
Objective Study the relationship between ABCDEF bundle compliance and outcomes including hospital survival and delirium-free and coma-free days (DFCFDs)
Methods(n=6064)
• QI initiative utilizing an interprofessional team (IPT) model to implement bundle• Seven community-based ICUs in California, calendar year 2014• Bundle elements implemented for every patient every day
Bundle Elements
A: SAT - turn of all sedation and pain meds unless active painB: SBT – safety screen then CPAP for 30 minsC1: Coordination of A & B – RN & RT communicationC2: PharmD PAD guidelines – light sedation, avoid BDZs, analgosedationD: CAM-ICU - evaluate delirium on both current and previous shiftsE: Mobilization – to maximum potential following safety screenF: Patient/Family – participated in rounds or family conference
Barnes-Daly et al. Crit Care Med 2017;45:171-178.
#FSHP2019
Barnes-Daly et al. Crit Care Med 2017;45:171-178.
#FSHP2019Components to SuccessComponents to Success• Tenets of the interprofessional team (IPT) model• Training provided to teams• Practice and embedding behaviors Collaborations Shared decision making
Barnes-Daly et al. Crit Care Med 2017;45:171-178.https://www.skmurphy.com/blog/2009/06/28/michael-schrage-on-innovation-collaboration...
#FSHP2019ConclusionsConclusionsPADIS builds upon the PAD guidelines with an emphasis on immobility and sleep disruption
Although the future of nefopam looks unclear, ketamine provides multiple opportunities to positively impact the care of critically ill patients
The implementation, integration, and evaluation of the guidelines is complex and requires a dedicated multidisciplinary team
67 68
69 70
71 72
7/10/2019
13
#FSHP2019
To PADIS and Beyond: Updates and Integration To PADIS and Beyond: Updates and Integration Michael Semanco, PharmD, BCPS, BCCCPClinical Pharmacy Specialist – Critical CareLakeland Regional HealthAugust 3, 2019
73